Daniel Noerenberg

Humboldt-Universität zu Berlin — Germany

Biochemistry, Genetics and Molecular Biology · Life Sciences

11h-index1.0kcitations50works3.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Research and Treatments(16), Immune Response and Inflammation(13), Nanoplatforms for cancer theranostics(11), S100 Proteins and Annexins(10), Cancer, Stress, Anesthesia, and Immune Response(10)

Publications50 total

Tracing Clonal Hematopoiesis and Tumor-Specific Mutations in Hematopoietic Progenitors of B Cell Non-Hodgkin Lymphoma (NHL) Patients
Blood·2024· 1 cited
Beyond the code: the role of histone methylation in cancer resistance and therapy
Signal Transduction and Targeted Therapy·2024· 8 citedOpen Access
An aggressive mediastinal <scp>EBV</scp>‐associated large <scp>B</scp> cell lymphoma
Histopathology·2024
Genetic Characterization of Primary Mediastinal B-Cell Lymphoma: Pathogenesis and Patient Outcomes
Journal of Clinical Oncology·2023· 30 cited
Transcriptional reprogramming by mutated IRF4 in lymphoma
Nature Communications·2023· 16 citedOpen Access
Frequent ZNF217 mutations lead to transcriptional deregulation of interferon signal transduction via altered chromatin accessibility in B cell lymphoma
Leukemia·2023· 11 citedOpen Access
Supplementary Table 1 from Therapeutic Efficacy of Bifunctional siRNA Combining TGF-β1 Silencing with RIG-I Activation in Pancreatic Cancer
2023Open Access
Supplementary Figure 5 from Therapeutic Efficacy of Bifunctional siRNA Combining TGF-β1 Silencing with RIG-I Activation in Pancreatic Cancer
2023Open Access
Supplementary Figure 1 from Systemic Cancer Therapy with a Small Molecule Agonist of Toll-like Receptor 7 Can Be Improved by Circumventing TLR Tolerance
2023Open Access
Data from Systemic Cancer Therapy with a Small Molecule Agonist of Toll-like Receptor 7 Can Be Improved by Circumventing TLR Tolerance
2023Open Access
Supplementary Table 1 from Therapeutic Efficacy of Bifunctional siRNA Combining TGF-β1 Silencing with RIG-I Activation in Pancreatic Cancer
2023Open Access
Supplementary Figure 4 from Therapeutic Efficacy of Bifunctional siRNA Combining TGF-β1 Silencing with RIG-I Activation in Pancreatic Cancer
2023Open Access
Data from Therapeutic Efficacy of Bifunctional siRNA Combining TGF-β1 Silencing with RIG-I Activation in Pancreatic Cancer
2023Open Access
Data from Therapeutic Efficacy of Bifunctional siRNA Combining TGF-β1 Silencing with RIG-I Activation in Pancreatic Cancer
2023Open Access
Supplementary Figure 4 from Systemic Cancer Therapy with a Small Molecule Agonist of Toll-like Receptor 7 Can Be Improved by Circumventing TLR Tolerance
2023Open Access
Supplementary Figure 4 from Therapeutic Efficacy of Bifunctional siRNA Combining TGF-β1 Silencing with RIG-I Activation in Pancreatic Cancer
2023Open Access
Supplementary Figure 4 from Systemic Cancer Therapy with a Small Molecule Agonist of Toll-like Receptor 7 Can Be Improved by Circumventing TLR Tolerance
2023Open Access
Supplementary Figure 2 from Systemic Cancer Therapy with a Small Molecule Agonist of Toll-like Receptor 7 Can Be Improved by Circumventing TLR Tolerance
2023Open Access
Supplementary Figure 3 from Therapeutic Efficacy of Bifunctional siRNA Combining TGF-β1 Silencing with RIG-I Activation in Pancreatic Cancer
2023Open Access
Supplementary Figure Legends 1-4 from Systemic Cancer Therapy with a Small Molecule Agonist of Toll-like Receptor 7 Can Be Improved by Circumventing TLR Tolerance
2023Open Access
page 1 of 3Next →

Frequent Co-authors

Stefan Endres(30), Jonathan Ellermeier(17), Jiwu Wei(17), Peter Duewell(17), Sabine Hoves(17), Mareike R. Stieg(17), Tina Adunka(17), Hans‐Joachim Anders(17), Doris Mayr(17), Hendrik Poeck(17), Gunther Hartmann(17), Max Schnurr(17), Frédérik Damm(16), Carole Bourquin(13), C. Hotz(13), Andreas Voelkl(13), Simon Heidegger(13), Laurin C. Roetzer(13), Bettina Storch(13), Nadja Sandholzer(13)